Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07830719) titled 'Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP' on Sept. 15.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Novartis Pharmaceuticals
Condition:
Coronary Artery Disease
Intervention:
Drug: YMI024
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: November 9, 2026
Target Sample Size: 180
To know more, visi...